Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $666000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 8.47% to $666000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 6.83% year-over-year, with the annual reading at $2.6 million for FY2025, 6.83% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $666000.0 at Artiva Biotherapeutics, up from $662000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $666000.0 in Q4 2025, with the low at $500000.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $607090.9, with a median of $614000.0 recorded in 2024.
  • Peak annual rise in Depreciation & Amortization (CF) hit 20.6% in 2024, while the deepest fall reached 3.37% in 2024.
  • Over 3 years, Depreciation & Amortization (CF) stood at $594000.0 in 2023, then increased by 3.37% to $614000.0 in 2024, then increased by 8.47% to $666000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $666000.0, $662000.0, and $641000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.